We demonstrate that although ApoB lowering is expected to have favorable effects on both PAD and CAD risk, the relative benefit is expected to be significantly greater for CAD risk reduction compared with PAD risk reduction. The gene discussed is APOB; the disease is peripheral arterial disease.